- Home
- CHMI vs AGEN Comparison
CHMI vs AGEN Comparison
Compare CHMI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- AGEN
- Stock Information
- Founded
- CHMI 2012
- AGEN 1994
- Country
- CHMI United States
- AGEN United States
- Employees
- CHMI N/A
- AGEN N/A
- Industry
- CHMI Real Estate Investment Trusts
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHMI Real Estate
- AGEN Health Care
- Exchange
- CHMI Nasdaq
- AGEN Nasdaq
- Market Cap
- CHMI 97.0M
- AGEN 87.7M
- IPO Year
- CHMI 2013
- AGEN 2000
- Fundamental
- Price
- CHMI $2.96
- AGEN $4.80
- Analyst Decision
- CHMI Hold
- AGEN Buy
- Analyst Count
- CHMI 2
- AGEN 4
- Target Price
- CHMI N/A
- AGEN $13.00
- AVG Volume (30 Days)
- CHMI 177.2K
- AGEN 1.6M
- Earning Date
- CHMI 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- CHMI 20.34%
- AGEN N/A
- EPS Growth
- CHMI N/A
- AGEN N/A
- EPS
- CHMI N/A
- AGEN N/A
- Revenue
- CHMI $27,506,000.00
- AGEN $99,524,000.00
- Revenue This Year
- CHMI N/A
- AGEN $12.69
- Revenue Next Year
- CHMI $54.92
- AGEN N/A
- P/E Ratio
- CHMI N/A
- AGEN N/A
- Revenue Growth
- CHMI 19.59
- AGEN N/A
- 52 Week Low
- CHMI $2.34
- AGEN $1.38
- 52 Week High
- CHMI $3.99
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- CHMI 46.58
- AGEN 54.50
- Support Level
- CHMI $2.87
- AGEN $4.38
- Resistance Level
- CHMI $3.04
- AGEN $5.20
- Average True Range (ATR)
- CHMI 0.05
- AGEN 0.57
- MACD
- CHMI -0.01
- AGEN -0.10
- Stochastic Oscillator
- CHMI 41.18
- AGEN 43.60
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).